To evaluate feasibility of percutaneous nephrolithotomy (PCNL) for complex nephrolithiasis in patients 80 years of age and older compared to younger individuals. From an institutional IRB-approved database, 1,647 patients were identified who underwent PCNL from 1999-2019. Patients were stratified by age: group 1 (20-59), group 2 (60-79), and group 3 (>80). Statistics were performed using […]
The aim of postoperative examination, treatment and follow-up of patients with urinary stone disease is a prevention of recurrence. A choice of method of prevention is based on the results of postoperative examination with consideration of etiological factors of urinary stone disease. An analysis of influence of osteoporosis and its causative factors on the recurrence […]
Renal stone disease is a very common medical problem in general population. As with invent of newer therapeutic modalities, ESWL is already losing its popularity. But we believe it as an effective way of treating renal stones. This study was conducted to evaluate any improvement in success rate of ESWL therapy for treating renal stones […]
With the increasing of the prevalence of pediatric urolithiasis (1-5%), retrograde intrarenal surgery (RIRS) is emerging as preferred option for the management of stones in pediatric patients. Although the principles of RIRS developed in adults can be applied in children, also expert adult endourologists feel uncomfortable to approach young patients due to long learning curve […]
Background: Percutaneous nephrolithotomy (PCNL) serves as the gold standard minimally invasive procedure to remove large renal stones. The puncture is made from the skin to the chosen calix under fluoroscopic guidance, although this remains a challenging technique. We describe the initial case of retrograde holmium laser acquired nephrostomy access. Case Presentation: In this study, we […]
Charles Drake: Good afternoon. I’d like to echo the previous of speakers by thanking Silke Gillessen, Silke and Aurelius for organizing a meeting that’s really seminal and really lets us to get up to date on many subjects. This is Columbia actually and if you look across your left there is William Oh sitting on […]
Eleni Efstathiou: Thank you very much for allowing me to present data and discuss something I’m not an expert on. Thank you. I come as a clinician and a physician, a person who can try to understand looking from the outside as all of us in this room how this field can get better with […]
Robert Reiter: Thank you. It’s an honor to be here and I want to thank Silke and Aurelius for the invitation to participate in what so far has been a really great meeting. So my job, my task is to really start this session about oligometastatic disease by providing hopefully some context, some definitions, and […]
Stefano Fanti: Let me get this opportunity to thank again the organizer because of the beautiful, incredible event, but also for another reason that possibly would be shown by my slides. This opportunity to networking is so important, the opportunity to meet friend, to meet colleagues, and exchange very important information, plan some future studies […]
Fred Saad: Thank you very much and thank you again to Silke and Aurelius for the invitation, and this has been another excellent meeting and I’m sure the one coming up is going to be again to meet our expectations. So I was given the task to talk about a subject that I thought was […]
